Kato Rans
Katholieke Universiteit Leuven
Internal medicineRadiologyUrologySurgeryOncologyLibrary scienceRetrospective cohort studyRandomized controlled trialClinical endpointBiochemical recurrenceAndrogen deprivation therapyHormonal therapyMetastasectomyMetastasisDiseaseProstatectomySurgical oncologyProstate cancerHormone therapyBladder cancerAbdominal aortaDisease burdenLymphadenectomyLymph nodeProstate-specific antigenWhole-PelvisMetastatic lesionsSalvage radiotherapyRefractoryRadiation therapyClinical trialTerm (time)Informed consentMedicineUrinary system
7Publications
2H-index
9Citations
Publications 10
Newest
#1Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
Last. G. De Meerleer (Katholieke Universiteit Leuven)H-Index: 9
view all 8 authors...
PURPOSE/OBJECTIVE(S) In metastatic castration-refractory prostate cancer (mCRPC), clinical progression usually implies the start of a new systemic treatment-line. When clinical progression is limited to a few new and/or progressive lesions, while all other lesions are still responsive to ongoing treatment, the term 'oligoprogression' is used. Retrospective data demonstrated that metastasis-directed therapy (MDT) to the oligoprogressive lesions substantially postponed the start of next-line syste...
Source
Source
#1Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
#2Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
Last. Kato Rans (Katholieke Universiteit Leuven)H-Index: 2
view all 13 authors...
In patients with prostate cancer who have a high risk of pelvic nodal disease, the use of elective whole pelvis radiotherapy is still controversial. Two large, randomised, controlled trials (RTOG 9413 and GETUG-01) did not show a benefit of elective whole pelvis radiotherapy over prostate-only radiotherapy. In 2020, the POP-RT trial established the role of elective whole pelvis radiotherapy in patients who have more than a 35% risk of lymph node invasion (known as the Roach formula). POP-RT stre...
Source
Source
#1Gaëtan DevosH-Index: 6
#2Charlien BerghenH-Index: 5
Last. G. De MeerleerH-Index: 9
view all 7 authors...
Source
#1Charlien BerghenH-Index: 5
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
Last. G. De MeerleerH-Index: 9
view all 8 authors...
Source
#1Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
Last. Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
view all 8 authors...
Radical prostatectomy is a well-established treatment option in the management of localized and locally advanced prostate cancer. An extended lymphadenectomy is performed in case of substantial risk for lymph node involvement. When biochemical recurrence (BCR) occurs, salvage radiotherapy (SRT) is performed. The benefit in terms of BCR-free survival (FS) and metastasis-FS by adding 6 months of androgen deprivation therapy (ADT) compared with SRT only has already been established. Retrospective e...
Source
#1Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
Last. Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
view all 11 authors...
BACKGROUND: Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2-3 years. A subgroup of those patients with mCRPC presents with oligoprogressive disease, with a limited number of progressive lesions while other metastases are still controlled by ongoing systemic treatment. METHODS: In this single arm prospective phase II trial, we aim to include 18 patients with oligoprogressive mCRPC (...
Source
#1Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
Last. Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
view all 8 authors...
For patients presenting with limited metastatic disease burden, known as the oligometastatic state of disease, a more aggressive treatment approach targeting the new or progressive metastatic lesions might improve patient outcome, with no or only limited toxicity to be expected from the treatment. This review provides an overview of the existing evidence and on-going trials on oligometastatic disease and metastasis-directed therapy in the field of renal, bladder and prostate cancer.
Source
#1Kato Rans (Katholieke Universiteit Leuven)H-Index: 2
#2Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
Last. G. De Meerleer (Katholieke Universiteit Leuven)H-Index: 9
view all 4 authors...
Abstract For patients experiencing biochemical recurrence in the absence of distant metastasis, salvage radiotherapy (SRT) with or without androgen deprivation therapy (ADT) is currently the only possible curative treatment option. Prostate-specific antigen (PSA) monitoring and the selected use of SRT has some advantages when compared with adjuvant radiotherapy. The most important one is avoidance of a potential overtreatment of patients who would never have disease progression, even in the pres...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.